MUIR: Plozasiran Reduces Triglyceride Levels in Mixed Hyperl

Phase 2b study results show that investigational plozasiran significantly reduced triglyceride-rich lipoproteins in patients with mixed hyperlipidemia.

Related Keywords

Christiem Ballantyne , , Arrowhead Pharmaceuticals Inc , Baylor University Christiem Ballantyne , Baylor College Of Medicine , Arrowhead Pharmaceuticals , Baylor University , Baylor College , Agent Targeting , New England Journal ,